ViraxImmune™ IVD Platform
Post-Acute Infection Syndrome (PAIS) / General Immune Profiling
DevelopmentActive; Preparing for FDA Pre-Submission Meeting
Key Facts
Indication
Post-Acute Infection Syndrome (PAIS) / General Immune Profiling
Phase
Development
Status
Active; Preparing for FDA Pre-Submission Meeting
Company
About Virax Biolabs
Virax Biolabs is pioneering immune profiling through its ViraxImmune™ platform, which utilizes peptide pools for T cell stimulation and analysis. The company is advancing a novel portfolio of FluoroSpot T cell diagnostics towards regulatory submission, with key partnerships including Emory University for clinical studies and an upcoming FDA pre-submission meeting. Their mission is to translate immunological insights into actionable diagnostics for complex, post-viral conditions, aiming to improve global health outcomes.
View full company profile